导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 5.98% | 1031/4773 |
| 近一周 | -3.62% | 4373/5462 |
| 近一月 | -6.27% | 3494/5421 |
| 近一季 | -14.44% | 4154/5209 |
| 近半年 | -0.89% | 1413/4920 |
| 近一年 | 11.47% | 917/4366 |
| 近两年 | 93.77% | 654/2954 |
| 近三年 | 42.82% | 660/2253 |
| 成立以来 | 58.67% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-1.39% 2272/4961 |
28.53% 1012/5312 |
- - |
- - |
| 2025 | 30.96% 1273/4813 |
6.32% 652/3635 |
2.67% 1435/4076 |
15.30% 2821/4524 |
4.05% 577/4813 |
| 2024 | 0.83% 2047/3463 |
-12.72% 2465/2808 |
-8.63% 2256/3014 |
23.54% 386/3129 |
2.33% 958/3463 |
| 2023 | 3.83% 259/2656 |
17.87% 170/2280 |
-0.71% 407/2385 |
-11.38% 2058/2515 |
0.11% 165/2655 |
| 2022 | -28.08% 1528/2207 |
-19.90% 1503/1919 |
0.29% 1565/2016 |
-15.21% 1245/2113 |
5.58% 457/2208 |
| 2021 | 29.16% 75/1822 |
-11.53% 1136/1255 |
25.24% 93/1330 |
3.17% 416/1466 |
12.99% 79/1822 |
| 2020 | - - |
- - |
18.95% 316/1067 |
6.60% 824/1164 |
-3.77% 1135/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 天弘恒生沪深港创新药精选50ETF | 0.8428 | 28.18% |
| 港股通药 | 0.8930 | 27.53% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.2971 | 26.78% |
| 华富中证港股通创新药指数型发起式C | 1.1445 | 26.30% |
| 万家中证港股通创新药ETF | 1.5973 | 26.27% |
| 景顺长城中证港股通创新药ETF | 1.6587 | 26.20% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2831 | 25.87% |
| 港医疗 | 0.8885 | 25.59% |
| 景顺长城中证港股通创新药ETF联接A | 1.4594 | 25.50% |
| 华富中证港股通创新药指数型发起式A | 1.1526 | 25.42% |
| 国寿安保创精选88ETF VS. 长安沪深300非周期A(740101) |